APRIL REED: Open Payments
NPI 1902490444 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,588 in 200 payments from 28 companies in 2025. Trend: 2023 $2,429 · 2024 $2,710 · 2025 $3,588
Food & beverage: $3,588
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 25 | $508 |
| ABBVIE INC. | 23 | $294 |
| Novo Nordisk Inc | 18 | $281 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $253 |
| Actelion Pharmaceuticals US, Inc. | 10 | $249 |
| Merck Sharp & Dohme LLC | 9 | $201 |
| GlaxoSmithKline, LLC. | 14 | $163 |
| Lilly USA, LLC | 12 | $159 |
| GENZYME CORPORATION | 6 | $120 |
| Axsome Therapeutics, Inc. | 6 | $118 |
Products named: TEZSPIRE, DUPIXENT, ZERBAXA, Wegovy, OFEV, OPSUMIT, Sunosi, GEMTESA.
Industry payments across AL — which companies pay providers there.
